Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.
Adult
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bendamustine Hydrochloride
/ therapeutic use
Carmustine
/ pharmacology
Cytarabine
/ therapeutic use
Etoposide
Hematopoietic Stem Cell Transplantation
/ methods
Humans
Lymphoma, Mantle-Cell
/ drug therapy
Melphalan
/ therapeutic use
Retrospective Studies
Transplantation, Autologous
/ methods
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
06
12
2021
accepted:
19
01
2022
revised:
18
01
2022
pubmed:
13
2
2022
medline:
13
4
2022
entrez:
12
2
2022
Statut:
ppublish
Résumé
Cytarabine-based immuno-chemotherapy followed by autologous stem cell transplantation (ASCT) consolidation is standard of care for fit patients with Mantle Cell Lymphoma (MCL). BEAM (Carmustine, Etoposide, Aracytine, Melphalan) is among the most frequently used conditioning regimen. Studies comparing BEAM with Bendamustine-EAM (BeEAM) have suggested that patients treated with BeEAM have a better progression-free survival (PFS). We performed a cross-study analysis to better evaluate BeEAM. Thirty-five patients from a retrospective study who received R-DHAP/BeEAM were compared to 245 patients from the LyMa trial (NCT00921414) who all received R-DHAP followed by R-BEAM. PFS and Overall Survival (OS) were estimated using Kaplan-Meier methods. At 2 years there was no difference between R-BEAM and BeEAM in either PFS (84.9% versus 87.9%; p = 0.95) or OS (91.8% versus 94.2%; p = 0.30). Analyses were repeated on a propensity score to reduce biases. Each patient from the BeEAM cohort (n = 30) was matched to three patients from the R-BEAM cohort (n = 90) for age, sex, MIPI score, pre-transplant status disease and rituximab maintenance (RM). PFS and OS at 2 years remained similar between R-BEAM and BeEAM with more renal toxicity in BeEAM group. MCL patients who received R-DHAP induction before ASCT have similar outcome after R-BEAM or BeEAM conditioning regimen.
Identifiants
pubmed: 35149851
doi: 10.1038/s41409-022-01596-8
pii: 10.1038/s41409-022-01596-8
doi:
Substances chimiques
Cytarabine
04079A1RDZ
Etoposide
6PLQ3CP4P3
Bendamustine Hydrochloride
981Y8SX18M
Melphalan
Q41OR9510P
Carmustine
U68WG3173Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
627-632Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Smedby KE, Hjalgrim H. Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol. 2011;21:293–8.
doi: 10.1016/j.semcancer.2011.09.010
Wang Y, Ma S. Risk factors for etiology and prognosis of mantle cell lymphoma. Expert Rev Hematol. 2014;7:233–43.
doi: 10.1586/17474086.2014.889561
Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388:565–75.
doi: 10.1016/S0140-6736(16)00739-X
Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377:1250–60.
doi: 10.1056/NEJMoa1701769
Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011;118:3419–25.
doi: 10.1182/blood-2011-04-351924
Chantepie SP, Garciaz S, Tchernonog E, Peyrade F, Larcher M-V, Diouf M, et al. Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers. Am J Hematol. 2018;93:729–35.
doi: 10.1002/ajh.25077
Ghesquières H, Dalban C, Nicolas-Virelizier E, Jardin F, Le Bras F, Le, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres†. Br J Haematol. 2021;192:e94–8.
doi: 10.1111/bjh.17279
Hueso T, Gastinne T, Garciaz S, Tchernonog E, Delette C, Casasnovas R-O, et al. Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers. Bone Marrow Transpl. 2020;55:1076–84.
doi: 10.1038/s41409-020-0783-y
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
doi: 10.1200/JCO.1999.17.4.1244
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with Ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–16.
doi: 10.1056/NEJMoa1306220
Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126:739–45.
doi: 10.1182/blood-2015-03-635326
Garciaz S, Coso D, Schiano de Collela J-M, Broussais F, Stoppa A-M, Aurran T, et al. Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity. Bone Marrow Transpl. 2016;51:319–21.
doi: 10.1038/bmt.2015.257